Real-world characteristics and safety outcomes of 10 000 eyes treated with intracanalicular dexamethasone insert: IRIS registry analysis 2019 to 2021.
The DEX insert was found to have comparable inflammation, lacrimal disorder, and IOP outcomes to alternate perioperative therapy after cataract surgery, and real-world safety outcomes in this cohort of more than 10,000 eyes were similar to those observed in prior DEX clinical trials.
Journal of cataract and refractive surgery2025 Nov 11 iop-medical-therapy